Proteorex Therapeutics Inc., a 2017 CAAP company, announced a research and development collaboration with Montreal-based Corbin Therapeutics.
As part of the collaboration, Proteorex will receive an undisclosed upfront payment, and downstream milestone-based payments.
Proteorex will utilize their award-winning targeted drug design chemistry platform in combination with Corbin's novel therapeutic approach to treating various inflammation-based diseases. The collaboration will identify small molecules which efficiently inhibit an important ubiquitin-specific protease, USP15.
Click here for the press release